uniQure N.V.
QURE$765M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaAMSTERDAM209 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
4
Next Catalyst
Aug 4, 2026
6wMarket Overview
Stock performance and key metrics
QURE News
Catalyst Timeline
4 upcoming, 0 past
Drug Pipeline
AMT-191
Fabry Disease
rAAV2/5-hNAGLU
Sanfilippo Syndrome B
AMT-162
Amyotrophic Lateral Sclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AMT-191 | Phase 2 | Fabry Disease | - | - |
rAAV2/5-hNAGLU | Phase 2 | Sanfilippo Syndrome B | - | - |
AMT-162 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply